Panbela Therapeutics, Inc.: 10-Q filed 2018-11-05
What Panbela Therapeutics, Inc. reported in its quarterly report filed 2018-11-05 (fiscal Q3 2018): 26 published measures, 72 facts as tagged in accession 0001437749-18-019460.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-11-05
- Fiscal period
- fiscal Q3 2018
- Accession
- 0001437749-18-019460 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Panbela Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 945,000 | USD | |
| At 2017-12-31 | 767,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | -542,000 | USD | |
| At 2017-12-31 | -3,689,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 239,000 | USD | |
| At 2017-12-31 | 152,000 | USD | |
| At 2017-09-30 | 943,000 | USD | |
| At 2016-12-31 | 438,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -927,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -5,165,000 | USD | 273 |
| 2011-01-01 to 2018-09-30 | 34,300,000 | USD | 2830 |
| 2017-07-01 to 2017-09-30 | -1,219,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -8,213,000 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | -2,225,000 | USD | 273 |
| 2017-01-01 to 2017-09-30 | -2,619,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 2,314,000 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 3,106,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | -34,318,000 | USD | |
| At 2017-12-31 | -29,153,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -54,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -163,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -197,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -460,000 | USD | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 1,202,000 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 1,167,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -917,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -3,254,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -1,045,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -4,207,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 892,000 | USD | |
| At 2017-12-31 | 767,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 3,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 1,763,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 474,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 1,145,000 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 1,487,000 | USD | |
| At 2017-12-31 | 4,170,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 1,017,000 | USD | |
| At 2017-12-31 | 1,196,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 450,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 1,475,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 530,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 1,955,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 5,060,594 | shares | |
| At 2017-12-31 | 3,841,652 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 33,612,000 | USD | |
| At 2017-12-31 | 25,625,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 159,000 | USD | |
| At 2017-12-31 | -165,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 53,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 140,000 | USD | |
| At 2017-12-31 | 1,254,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -672,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -4,841,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -1,281,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -8,459,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 467,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 1,779,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 515,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 2,252,000 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -90,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -362,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 75,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 264,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -64,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -2,074,000 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -371,000 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -4,466,000 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 61,000 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 5,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 186,000 | USD | 273 |
| 2017-01-01 to 2017-09-30 | -654,000 | USD | 273 |
Inspect the source
- Entity
- Panbela Therapeutics, Inc. / CIK 0001029125
- Captured
- 2026-09-21T17:17:41.392Z
- SEC response SHA-256
5fda5ff967a840ef3f57f70eeef789c92fe69418b24473bec9634b9f66bd5e2d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001029125.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))